Barbiturates enhance the binding of azepam to benzodiazepine receptor sites in rat brain. This effect occurs at pharmacologically relevant concentrations of barbiturates, and the relative activity of a series of compounds correlates highly with anesthetic activity of the barbiturates and with their ability to enhance postsynaptic inhibitory responses to the neurotransmitter 'y-aminobutyric acid. Barbiturate enhancement of benzodiazepine binding is stereospecific, with the more active anesthetic isomers of Nl-methylbarbiturates being also more active than their stereoisomers in enhancing benzodiazepine binding. The active barbiturates produce a reversible enhancement in the affinity of specific benzodiazepine binding with no effect on the number of binding sites. The barbiturate enhancement, but not the baseline benzodiazepine binding, is competitively inhibited by the convulsant icrotoxinin (at 1-10 ,M), a drug that has been shown to labe barbiturate-sensitive brain membrane sites related to the 7-aminobutyric acid receptor-ionophore complex. The barbiturate effect is also dependent upon the presence of certain anions, and only those anions, that penetrate the chloride channels regulated by "y-aminobutyric acid receptors. These results suggest that picrotoxin-sensitive barbiturate binding sites are coupled to benzodiazepine receptors in the y-aminobutyric acid receptor-ionophore complex, and that these binding sites have the properties of pharmacologically relevant receptors that mediate at least part of the action of various nervous system depressant and excitatory drugs.
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Barbiturates are general central nervous system depressants that are used clinically for anesthetic, sedative-hypnotic, and anticonvulsant actions. The site (or sites) of action of these drugs is generally considered to be the excitable nerve membrane, perhaps involving a decrease in excitatory synaptic transmission (1, 2) or an increase in inhibitory synaptic transmission (2, 3) . It is not known whether the drug action involves any specific receptor sites or more nonspecific membrane perturbations. The latter type of effects are known to occur in biological systems exposed to high concentrations (>0.3 mM) of barbiturates (4), whereas anesthetic actions are thought to involve somewhat lower concentrations (1-200 AM) (1) .
Recent electrophysiological studies suggest that barbiturates can enhance or mimic the postsynaptic response to the inhibitory neurotransmitter y-aminobutyric acid (GABA) (2, 3, 5, 6 ). This appears to involve a potentiation of chloride ion conductance activated by GABA binding to its receptor site (3). Barbiturates can directly activate chloride ion channels or prolong the lifetime of GABA-activated channels (3), an action which will also effectively reverse the antagonism of GABA postsynaptic responses by bicuculline (7) and picrotoxin (2) . In vitro studies suggest that at therapeutic concentrations, barbiturates do not affect GABA receptor binding or presynaptic synthesis, release, or reuptake of GABA (8 (9, 10) , submicromolar concentrations of excitatory barbiturates (9, 10) , and other convulsant drugs that can block GABA synapses (10, 11) .
Another class of central nervous system-depressant drugs that may act at least in part by enhancement of GABAergic inhibitory synaptic transmission (5) are the benzodiazepines (BZ), such as diazepam. These compounds bind to high-affinity receptor sites in the central nervous system with a chemical specificity that correlates well with the anxiolytic, anticonvulsant, hypnotic, and muscle-relaxant activity of BZ (12, 13) . The BZ receptors are at least partly coupled to GABA receptor binding sites in the central nervous system, as shown by allosteric activation by GABA of BZ binding in membranes (14) . Consistent with the different pharmacological profiles of barbiturates and BZ, barbiturates do not inhibit BZ binding sites (12) (13) (14) , and no in vitro coupling has so far been demonstrated between barbiturates or other drugs binding to the picrotoxinin-labeled sites and GABA receptors (8) (9) (10) (11) .
We now provide evidence for in vitro coupling between barbiturate/picrotoxin binding sites and BZ receptors in the central nervous system. This barbiturate binding site has a specificity that correlates very well with the anesthetic and GABA-enhancing actions of these drugs and, thus, can be designated as a barbiturate receptor.
MATERIALS AND METHODS
[N-methyl-3H]Diazepam (83.5 Ci/mmol; 1 Ci = 3.7 X 1010 becquerels) was purchased from New England Nuclear. Non (14) while minimizing damage to the fragile binding sites for picrotoxinin and barbiturates (8) (9) (10) (11) . The pellet was resuspended to a final protein concentration of 0.5-2.0 mg/ml in buffer. Aliquots (0.8 ml) of the membrane suspension were incubated in triplicate for 60min at 00C with 0.5 nM [3H]diazepam with and without drugs and in a total volume of 1 ml. At the end of the incubation, the membranes were rapidly trapped on Whatman GF/B filters. Two 2-ml additions of 0.2 M NaCI wete added to the incubation vial and poured onto the filter. The filters were dried and put into plastic vials. Five milliliters of Aquasol/toluene, 2:1 (vol/vol; New England Nuclear), were added, and vials were assayed for radioactivity in a Beckman 3155T scintillation counter. Efficiency (35%) was routinely determined with [3H]toluene. Background was determined in the presence of 10MM unlabeled diazepam and usually was 5% of the total radioactivity. in Fig. 3 with barbiturate are in each case compared to control 3H-labeled BZ binding carried out in buffer containing the corresponding identical chloride concentration without added barbiturate. At a given concentration of barbiturate, approximately 20-30 mM chloride was needed for a half-maximal effect and at least 100 mM chloride for the maximal effect. (19) . Likewise, the depressant (-) isomer of MPPB enhanced BZ binding more potently than the (+) isomer, which has been reported to produce central nervous system excitation rather than depression (20) . The presence of (+)-MPPB could also reverse the enhancement of BZ binding by (-)-MPPB ( Fig.  4B ; Table 2 ). The (-) isomer of pentobarbital was more potent than the (+) isomer; the former compound is reported to depress neuronal activity, whereas the latter has some excitatory action on cells (3) .
RESULTS
Another convulsant barbiturate, 5-ethyl-5-(2-cyclohexylideneethyl)barbituric acid (CHEB) gave only weak enhancement of BZ binding. However, DMBB was the most potent of all barbiturates tested in enhancing BZ binding (Table 2 ). This racemic mixture contains both the excitatory (+) isomer and the depressant (-) isomer; the (-) isomer has been reported to have hypnotic activity greater than that of pentobarbital (21) .
Thus, the enhancement of BZ binding by the (W) pair could be due to the (-) isomer.
The barbiturate enhancement of benzodiazepine binding to sites that are known to be coupled to postsynaptic GABA receptor-ionophores, the chemical specificity of the effect, its reversal by picrotoxinin, and the anion requirement all support the conclusion that this in vitro barbiturate action involves a pharmacologically relevant receptor site for these drugs. (14) , which suggests a physical coupling between these two classes of receptors, at least in part.
Another class of drugs, the pyrazolopyridine compounds (e.g., etazolate, or SQ 20009), enhances BZ binding in vitro, but not by a direct interaction of this drug with GABA receptors (22, 23) . The enhancement of BZ binding by etazolate was found to be inhibited by picrotoxin (17) . We . This is consistent with etazolate and barbiturates acting at the same site (a picrotoxin-sensitive site), which is distinct from the GABA receptor site. Furthermore, the enhancement of BZ binding by GABA is not strictly anion dependent (17, 22, 23) , whereas the enhancement by both etazolate (17) and barbiturates (this study) is strictly dependent upon certain anions. Also, GABA enhancement is blocked by 20 /M piperidine-4-sulphonic acid and imidazole acetic acid (14) , whereas that of barbiturates or etazolate is not (unpublished data) . This latter observation also shows that the barbiturate effect is not mediated by GABA.
The anions that will support barbiturate enhancement of BZ binding are the same anions that enhance basal BZ binding (16) and are exactly those anions that permeate anion channels activated in spinal cord inhibitory synapses (15) , now known to be GABAergic (2) . Similar concentrations (20-30 mM) of chloride ions are required for half-maximal enhancement of baseline (16) or the barbiturate enhancement (this study) of BZ binding. A similar ion specificity was observed for enhancement of bicuculline inhibition of GABA receptor binding, whereas the apparent affinity of a GABA agonist such as 3-aminopropanesulfonic acid was not altered (26) . These results are consistent with the suggestion that both BZ receptors (16) and the barbiturate receptor sites described here are at least partly coupled to chloride channels and that these receptors mediate the action of these drugs in enhancing the function of GABA receptor-activated chloride channels.
Drugs that bind to picrotoxin sites, such as barbiturates (9) (10) (11) , etazolate (24, 25 ; unpublished data), and a convulsant BZ, R05-3663 (10, 24, 25) , have been shown to produce both modest allosteric perturbations of GABA receptor binding in vitro (27, 28) and modulation of GABA enhancement of BZ binding (28) (29) (30) . In agreement with our results, barbiturates were also seen to enhance baseline BZ binding (30) . In the light of all these in vitro interactions that take place in cell-free membranes at 00C on a very rapid time scale and corresponding interactions of barbiturates with GABA-regulated chloride channels in intact cells (3), it seems likely that the membrane macromolecules must be intimately associated in a membrane complex. Accordingly, we have proposed a three receptor/chloride ion channel model for the postsynaptic GABA receptor-ionophore complex (24, 25) .
The activity for several barbiturates in enhancing BZ binding in vitro correlates well with pharmacological activity of these drugs measured both in an electrophysiological study with isolated central nervous system tissue (7) and in the intact animal (18) , despite obvious potential pharmacokinetic problems in the latter case (i.e., drug metabolism, tissue distribution, serum protein binding, etc. can alter the in vivo drug potencies). This correlation strongly suggests that the barbiturate receptor that is coupled to the BZ receptor is involved in the central nervous system depressant actions of barbiturates. No such correlation can be made with the antiepileptic action of barbiturates, but it is possible that this drug receptor plays some role in the anticonvulsant action of barbiturates as well.
The barbiturate enhancement of BZ binding was stereospecific, as required for the stereospecific anesthetic activity of N'-methyl barbiturates, such as hexobarbital and MPPB: The (+)-hexobarbital and the (-)-MPPB isomers are more potent than their stereoisomers in both anesthetic potency (19, 20) and in this binding assay.
Whereas convulsant barbiturates are more potent than depressant barbiturates in inhibiting DHP binding (9, 11) , some convulsant barbiturates such as CHEB only weakly enhanced BZ binding and did not inhibit the enhancement by other barbiturates. (±)-DMBB, on the other hand, potently enhanced BZ binding. This barbiturate contains an optically active carbon in one of the C5 sidechains (1,3-dimethylbutyl) , and the (+) isomer is excitatory whereas the (-) isomer is depressant (21) . We have used the racemic pair in these studies, the pure isomers being unavailable. Nevertheless, the lack of a potent picrotoxin-like effect of (±)-DMBB and CHEB on the barbiturate enhancement of BZ binding is unexplained. Another barbiturate with an optically active carbon in the C5 side chain is pentobarbital. Here the (-) isomer is more active in the enhancement of BZ binding. This isomer produces an inhibitory chloride conductance in neurons and a smooth hypnosis in intact animals, whereas the (+) isomer can excite neurons and induce excitability in animals before they become anesthetized bye the drug (3).
It might be only the long-term depressant action of barbiturates that is related to enhancement of BZ binding, or perhaps the sites for both depressant and excitatory actions of barbiturates are coupled to BZ receptors, and the relative allosteric perturbation is unrelated to mechanism in intact cells. 
